ClinicalTrials.gg
RecruitingNCT07837427Updated Sep 23, 2026

Effect of Irrigation Pressure on Postoperative Complications and Surgical Field Clarity in Unilateral Biportal Endoscopic Surgery

An interventional study of Unilateral Biportal Endoscopic Surgery in Lumbar Disc Herniation, Lumbar Spinal Stenosis and Lumbar Degenerative Disease, sponsored by Fan Zhang. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-23.

Sponsored by Fan Zhang · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Feb 2026, registered Sep 2026).
  • Started Feb 2026; still recruiting 9 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study is being done to find out if the height of the fluid bag and the direction of the surgical cut affect the pressure of the fluid used during unilateral biportal endoscopic (UBE) spine surgery. UBE is a minimally invasive surgery for the spine. During this surgery, fluid is used to keep the surgical area clear and to control bleeding. The pressure of this fluid may affect how clear the surgical view is, how much bleeding occurs, and how well patients recover after surgery. We will also collect disc tissue removed during surgery to study how disc degeneration is related to factors such as sex, age, mechanical stress, and injury. About 80 patients aged 18 to 75 who are scheduled for UBE surgery at our hospital will take part. Patients will be randomly assigned to one of four groups based on two things: the height of the fluid bag (0.9 meters or 1.0 meters) and the direction of the surgical cut (horizontal or vertical). We will measure the fluid pressure around the spinal covering during surgery and record how clear the surgical view is. After surgery, we will track patients' pain and recovery for at least 6 months. This study has been approved by the hospital ethics committee.

Read the detailed description

Background: Unilateral biportal endoscopy (UBE) is a minimally invasive spine surgery technique that has been increasingly used for lumbar disc herniation, spinal stenosis, and other degenerative conditions. Irrigation fluid is essential in UBE to maintain the surgical space and control bleeding. However, the pressure of irrigation fluid may be associated with complications such as neck pain, seizures, and increased intracranial pressure. The height of the fluid bag and the direction of the surgical incision are two controllable factors that may influence actual irrigation pressure and surgical field clarity, but prospective clinical evidence is lacking.

Objective: This study aims to investigate the effects of different fluid bag heights (0.9 m vs. 1.0 m) and incision directions (horizontal vs. vertical) on irrigation pressure, surgical field clarity, blood loss, and early postoperative pain and functional recovery in patients undergoing UBE surgery. Additionally, disc tissue collected during surgery will be used to explore the relationship between disc degeneration and factors such as sex, age, mechanical stress, and injury.

Design: This is a single-center, prospective, randomized controlled trial. Approximately 80 patients scheduled for UBE surgery at the First Affiliated Hospital of Kunming Medical University will be enrolled. Patients will be randomly assigned to one of four groups: (1) 0.9 m fluid bag height + horizontal incision; (2) 0.9 m fluid bag height + vertical incision; (3) 1.0 m fluid bag height + horizontal incision; (4) 1.0 m fluid bag height + vertical incision. Intraoperative irrigation pressure around the dura will be continuously measured. Surgical field clarity, blood loss, and early postoperative outcomes will be recorded. Patients will be followed for at least 6 months.

02

Conditions studied

  • Lumbar Disc Herniation
  • Lumbar Spinal Stenosis
  • Lumbar Degenerative Disease

Keywords

  • Unilateral Biportal Endoscopy
  • UBE
  • Irrigation Pressure
  • Fluid Bag Height
  • Incision Direction
  • Surgical Field Clarity
  • Postoperative Recovery
03

In context

Intervertebral Disc Displacement

474 studies on the registry are indexed under Intervertebral Disc Displacement; 100 are open to participants now.

This study's planned enrollment of 80 is above the median of 63 across 344 interventional studies indexed under Intervertebral Disc Displacement.

Browse Intervertebral Disc Displacement studies →

Lead sponsor

This is the only study on the registry with Fan Zhang as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >= 18 years and \< 75 years.
  • Patients scheduled for unilateral biportal endoscopic (UBE) surgery for lumbar degenerative disease at the First Affiliated Hospital of Kunming Medical University between February 2026 and December 2027.
  • Follow-up duration > 6 months.
  • Complete clinical and follow-up data available.
  • Voluntary participation and signed .

Exclusion criteria

Exclusion Criteria:

  • History of tuberculosis, infection, tumor, or trauma.
  • Severe cardiac, hepatic, or renal insufficiency.
  • History of chronic lung disease, liver disease, infection, diabetes, or renal insufficiency.
  • Psychiatric disorders or inability to comply with follow-up.
  • Severe osteoporosis.
  • Pregnant or lactating women.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    0.9 m Fluid Bag Height + Transverse Incision

    UBE surgery with 0.9 m fluid bag height and transverse incision.

    Procedure: Unilateral Biportal Endoscopic Surgery

  • Experimental
    0.9 m Fluid Bag Height + Longitudinal Incision

    UBE surgery with 0.9 m fluid bag height and longitudinal incision.

    Procedure: Unilateral Biportal Endoscopic Surgery

  • Experimental
    1.0 m Fluid Bag Height + Transverse Incision

    UBE surgery with 1.0 m fluid bag height and transverse incision.

    Procedure: Unilateral Biportal Endoscopic Surgery

  • Experimental
    1.0 m Fluid Bag Height + Longitudinal Incision

    UBE surgery with 1.0 m fluid bag height and longitudinal incision.

    Procedure: Unilateral Biportal Endoscopic Surgery

Interventions

  • ProcedureUnilateral Biportal Endoscopic Surgery

    UBE surgery performed with specified fluid bag height (0.9 m or 1.0 m) and incision direction (transverse or longitudinal).

06

What researchers measure

Primary outcomes

  1. Irrigation pressure around the dura

    Intraoperative irrigation pressure around the dura measured continuously during UBE surgery.

    Time frame: During surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared because the study involves a small sample of patients from a single center, and the data contain sensitive personal and surgical information. Protecting participant privacy and complying with local ethics regulations are the primary reasons for not sharing the data.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Dec 2027, 22 months after the start.

Of 178 non-industry interventional studies with no phase under Intervertebral Disc Displacement, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 23. This study's planned 22 months is above that.

Counting every sponsor, half of 191 studies reached it within 12 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2026
First posted
Sep 23, 2026
StartActual
Feb 5, 2026
Primary completionEst.
Dec 2027
CompletionEst.
Jan 2028
Last update
Sep 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07837427
Lead sponsor
Fan Zhang
Collaborators
National Natural Science Foundation of China
Responsible party
Fan Zhang (The First Affiliated Hospital of Kunming Medical University, First Affiliated Hospital of Kunming Medical University) — Sponsor-investigator
First posted
Sep 23, 2026
Start date
Feb 5, 2026
Primary completion
Dec 2027 (estimated)
Completion
Jan 2028 (estimated)
Last update
Sep 23, 2026

Study contacts

Fan Zhang, MD
Contact
zhangfan4@kmmu.edu.cn
+86 15087160418

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion